The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $136.09

Today's change-1.46 -1.06%
Updated September 4 4:07 PM EDT. Delayed by at least 15 minutes.
 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $136.09

Today's change-1.46 -1.06%
Updated September 4 4:07 PM EDT. Delayed by at least 15 minutes.

Edwards Lifesciences Corp crosses below 200-day moving average

Edwards Lifesciences Corp closed lower Friday, dropping (U.S.)$1.46 or 1.06% to (U.S.)$136.09 and crossing below its 200-day moving average. Shares have lost 5.95% over the last five days, but have gained 6.84% over the last year to date. This security has outperformed the S&P 500 by 42.07% during the last year.

Key company metrics

  • Open(U.S.) $136.17
  • Previous close(U.S.) $137.55
  • High(U.S.) $137.31
  • Low(U.S.) $134.62
  • Bid / Ask-- / --
  • YTD % change+6.84%
  • Volume642,895
  • Average volume (10-day)1,308,289
  • Average volume (1-month)1,107,390
  • Average volume (3-month)1,105,785
  • 52-week range(U.S.) $97.07 to (U.S.) $159.00
  • Beta0.70
  • Trailing P/E33.93×
  • P/E 1 year forward31.16×
  • Forward PEG2.26×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $4.01
Updated September 4 4:07 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.08%

Based on its net profit margin of 18.08%, Edwards Lifesciences Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.87%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue617590618607
Total other revenue--------
Total revenue617590618607
Gross profit458454458439
Total cost of revenue159136160168
Total operating expense475428485487
Selling / general / administrative214203223222
Research & development98868488
Depreciation / amortization--------
Interest expense (income), net operating4444
Unusual expense (income)10114
Other operating expenses, total0001
Operating income142163133121
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax142163133121
Income after tax11312310995
Income tax, total30392426
Net income11312310995
Total adjustments to net income--------
Net income before extra. items11312310995
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items11312310995
Inc. avail. to common incl. extra. items11312310995
Diluted net income11312310995
Dilution adjustment0----0
Diluted weighted average shares110110110108
Diluted EPS excluding extraordinary itemsvalue per share1.021.121.000.87
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.031.121.080.90